SNS-101 is under clinical development by Sensei Biotherapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SNS-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sensei Biotherapeutics overview
Sensei Biotherapeutics (Sensei) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes innovative immuno-oncology medicines. The company offering products include SNS-101, SNS-102 and SNS-103. The company’s patented and proprietary technology platform SPIRIT, creates novel therapies that target neoantigens or altered self-antigens. Sensei is advancing a new class of immuno-oncology therapies to stimulate the immune system to recognize cancer-specific antigens and attack cancer cells. It develops and commercializes an integrated set of diagnostics and therapeutics for cancer. Sensei is headquartered in Rockville, Maryland, the US.
For a complete picture of SNS-101’s drug-specific PTSR and LoA scores, buy the report here.